219626-94-5

Basic information

• Product Name: L-Cysteine, S-(cyclohexylmethyl)-N-[(1,1-dimethylethoxy)carbonyl]-
• CAS NO: 219626-94-5
• Molecular Formula: C15H27NO4S
• Molecular Weight: 317.45
• Mol File: 219626-94-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: L-Cysteine, S-(cyclohexylmethyl)-N-[(1,1-dimethylethoxy)carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Cysteine, S-(cyclohexylmethyl)-N-[(1,1-dimethylethoxy)carbonyl]-(219626-94-5)
• EPA Substance Registry System: L-Cysteine, S-(cyclohexylmethyl)-N-[(1,1-dimethylethoxy)carbonyl]-(219626-94-5)

Safety Data

• Hazardous Substances Data: 219626-94-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 473421-00-0 (R)-2-Amino-3-cyclohexylmethylsulfanyl-propionic acid 
• 2550-36-9 Cyclohexylmethyl bromide 
• 52-90-4 L-Cysteine 

Downstream Products

• 219624-82-5 (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide 
• 219624-99-4 (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide 
• 253306-09-1 (2R)-N-(4-hydroxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide 
• 219625-01-1 (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonyl-aminopropanamide 
• 219625-12-4 (2R)-N-(4-benzyloxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide 
• 219625-03-3 (2R)-N-(4-phenoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethyl-thiopropanamide 
• 573990-55-3 2-amino-3-cyclohexylmethylsulfanyl-N-(4-hydroxy-benzyl)-propionamide 
• 573990-54-2 2-amino-3-cyclohexylmethylsulfanyl-N-(4-nitro-benzyl)-propionamide 
• 573990-53-1 2-amino-3-cyclohexylmethylsulfanyl-N-(4-dimethylamino-benzyl)-propionamide 
• 473421-33-9 2-amino-3-cyclohexylmethylsulfanyl-N-(4-phenoxy-benzyl)-propionamide 
• 573990-56-4 2-amino-N-(4-benzyloxy-benzyl)-3-cyclohexylmethylsulfanyl-propionamide 
• 219625-66-8 (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide 

Relevant articles and documents

Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-XLand BCL-2

The BCL-2 family of proteins (including the prosurvival proteins BCL-2, BCL-XL, and MCL-1) is an important target for the development of novel anticancer therapeutics. Despite the challenges of targeting protein-protein interaction (PPI) interfaces with small molecules, a number of inhibitors (called BH3 mimetics) have entered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, new validated chemical series are desirable. Here, we outline the crystallography-guided development of a structurally distinct series of BCL-XL/BCL-2 inhibitors based on a benzoylurea scaffold, originally proposed as α-helix mimetics. We describe structure-guided exploration of a cryptic "p5"pocket identified in BCL-XL. This work yields novel inhibitors with submicromolar binding, with marked selectivity toward BCL-XL. Extension into the hydrophobic p2 pocket yielded the most potent inhibitor in the series, binding strongly to BCL-XL and BCL-2 (nanomolar-range half-maximal inhibitory concentration (IC50)) and displaying mechanism-based killing in cells engineered to depend on BCL-XL for survival.

Amino acid derivatives and drugs containing the same as the active ingredient

The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification). The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain.

Structure-activity study of L-amino acid-based N-type calcium channel blockers

Synthesis and structure-activity relationship (SAR) study of L-amino acid-based N-type calcium channel blockers are described. The compounds synthesized were evaluated for inhibitory activity against both N-type and L-type calcium channels focusing on sel